These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37379240)

  • 1. Novel promising benzoxazole/benzothiazole-derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis.
    Elkady H; El-Adl K; Sakr H; Abdelraheem AS; Eissa SI; El-Zahabi MA
    Arch Pharm (Weinheim); 2023 Sep; 356(9):e2300097. PubMed ID: 37379240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, anticancer evaluation,
    El-Zahabi MA; Elkady H; Sakr H; Abdelraheem AS; Eissa SI; El-Adl K
    J Biomol Struct Dyn; 2023; 41(24):15106-15123. PubMed ID: 36889930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents.
    El-Zahabi MA; Sakr H; El-Adl K; Zayed M; Abdelraheem AS; Eissa SI; Elkady H; Eissa IH
    Bioorg Chem; 2020 Nov; 104():104218. PubMed ID: 32932121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Biological Evaluation of New Potential Unusual Modified Anticancer Immunomodulators for Possible Non-Teratogenic Quinazoline-Based Thalidomide Analogs.
    Mabrouk RR; Abdallah AE; Mahdy HA; El-Kalyoubi SA; Kamal OJ; Abdelghany TM; Zayed MF; Alshaeri HK; Alasmari MM; El-Zahabi MA
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, anticancer evaluation, and
    Kotb AR; Abdallah AE; Elkady H; Eissa IH; Taghour MS; Bakhotmah DA; Abdelghany TM; El-Zahabi MA
    RSC Adv; 2023 Apr; 13(16):10488-10502. PubMed ID: 37021105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of some novel benzothiazole/benzoxazole and/or benzimidazole derivatives incorporating a pyrazole scaffold as antiproliferative agents.
    Abdelgawad MA; Bakr RB; Omar HA
    Bioorg Chem; 2017 Oct; 74():82-90. PubMed ID: 28772160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
    El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
    Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, anticancer evaluation and molecular docking of new benzothiazole scaffolds targeting FGFR-1.
    Abd El-Meguid EA; Mohi El-Deen EM; Moustafa GO; Awad HM; Nossier ES
    Bioorg Chem; 2022 Feb; 119():105504. PubMed ID: 34836644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
    El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
    Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
    Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis,
    Taghour MS; Mahdy HA; Gomaa MH; Aglan A; Eldeib MG; Elwan A; Dahab MA; Elkaeed EB; Alsfouk AA; Khalifa MM; Eissa IH; Elkady H
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2063-2077. PubMed ID: 35875937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
    Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
    Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and
    Al-Sanea MM; Hamdi A; Mohamed AAB; El-Shafey HW; Moustafa M; Elgazar AA; Eldehna WM; Ur Rahman H; Parambi DGT; Elbargisy RM; Selim S; Bukhari SNA; Magdy Hendawy O; Tawfik SS
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166036. PubMed ID: 36691927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.